Aurigene (a wholly owned subsidiary of Dr. Reddy’s Laboratories) is a leading Contract Research, Development, and Manufacturing Organization (CRDMO) with over two decades of experience in drug discovery and development. Aurigene’ s mission is to accelerate the development and delivery of innovative medicines to patients through an efficient drug discovery process. In alignment with this mission, Aurigene added the following tools to its service offerings:
- Computer Aided Drug Design (CADD) & Bioinformatics: A unique blend of traditional CADD, physics-based simulation, and bioinformatics applications
- Aurigene.AI: An AI-assisted drug discovery platform
- Aurimine: A virtual database comprising over 12 billion compounds
These innovations reinforce Aurigene’ s commitment to advancing drug discovery and bringing innovative medicines to realization.
Aurigene.AI features a meticulously curated compound database validated with structure normalization rules, continuously expanding using both in-house and public domain information. This robust database—currently containing 180 million compounds and 1.6 million validated bioassay data points—serves as a powerful search engine and training ground for AI algorithms. It is searchable via structure, property, or semantic queries to extract relevant information for specific purposes.
Aurigene.AI also allows extensive customization by incorporating multiple AI models into a single interface. It serves as a one-stop shop for a wide variety of top-tier predictive and generative AI models, alongside computational and CADD models. As of now, the platform includes 11 generative AI models, 4 predictive AI models, and 8 computational/CADD models. This modular and embedded design enables Aurigene’ s scientific experts to cherry-pick the right combination of models for targeted applications.
Descargo de responsabilidad
Ninguna información en este sitio web, incluyendo cualquier referencia a cualquier producto o servicio, constituye una oferta de venta ni se interpretará como tal. Los productos protegidos por patentes válidas no se ofrecen ni suministran para uso comercial. Sin embargo, en ciertos casos, a discreción exclusiva de Dr. Reddy's y sujeto a los requisitos legales locales, las cantidades de investigación de dichos productos pueden ofrecerse para fines de presentaciones regulatorias según la Sección 107A de la Ley de Patentes de la India (exención de Bolar), donde existan dichas exenciones regulatorias. Los compradores deben realizar su propia evaluación del producto o servicio, incluyendo el escenario de patentes en sus respectivos mercados, y serán responsables de todas las responsabilidades relacionadas con las patentes. Dr. Reddy's renuncia a todas las garantías, expresas o implícitas, incluyendo, entre otras, las garantías de comerciabilidad, idoneidad para un propósito particular y no infracción.